Baxdrostat

Chemical compound From Wikipedia, the free encyclopedia

Baxdrostat, sold under the brand name Baxfendy, is a medication used for the treatment of hypertension (high blood pressure).[1] It is an aldosterone synthase inhibitor.[1] It is taken by mouth.[1]

Trade namesBaxfendy
Other namesRO-6836191
AHFS/Drugs.comMonograph
MedlinePlusa626070
Quick facts Clinical data, Trade names ...
Baxdrostat
Molecular structure of baxdrostat
3D representation of a baxdrostat molecule
Clinical data
Trade namesBaxfendy
Other namesRO-6836191
AHFS/Drugs.comMonograph
MedlinePlusa626070
License data
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
  • N-[(8R)-4-(1-methyl-2-oxo-1,2,3,4-tetrahydro-6-quinolinyl)-5,6,7,8-tetrahydro-8-isoquinolinyl]propanamide
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC22H25N3O2
Molar mass363.461 g·mol−1
3D model (JSmol)
  • CCC(=O)N[C@@H]1CCCC2=C(C=NC=C12)C3=CC=C4N(C)C(=O)CCC4=C3
  • InChI=1S/C22H25N3O2/c1-3-21(26)24-19-6-4-5-16-17(12-23-13-18(16)19)14-7-9-20-15(11-14)8-10-22(27)25(20)2/h7,9,11-13,19H,3-6,8,10H2,1-2H3,(H,24,26)/t19-/m1/s1
  • Key:VDEUDSRUMNAXJG-LJQANCHMSA-N
Close

Baxdrostat was approved for medical use in the United States in May 2026.[2]

Medical uses

Baxdrostat is indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adults who are not adequately controlled on other agents.[1]

Mechanism of action

Aldosterone dysregulation contributes significantly to the pathogenesis of resistant hypertension.[3] While conventional drugs act by blocking the mineralocorticoid receptor, baxdrostat, an aldosterone synthase inhibitor, targets the aldosterone synthesis directly.[4]

History

Clinical trials

BrigHTN

In adults with treatment-resistant hypertension, treatment with baxdrostat at doses of 1 mg or 2 mg daily produced significantly greater reductions in systolic blood pressure over 12 weeks compared to placebo.[5]

BaxHTN

BaxHTN is a phase III trial.[6] It found that adding once-daily baxdrostat to standard antihypertensive therapy led to significantly greater reductions in seated systolic blood pressure at 12 weeks compared with placebo, in adults with uncontrolled or resistant hypertension.[7][6]

Bax24

Treatment with a once-daily 2mg dose of baxdrostat resulted in a clinically significant reduction in ambulatory systolic blood pressure reading over 12 weeks compared to placebo. A side effect of hyperkalaemia was noted.[8]

Society and culture

Baxdrostat was approved for medical use in the United States in May 2026.[2][9]

Names

Baxdrostat is the international nonproprietary name.[10]

Baxdrostat is sold under the brand name Baxfendy.[1]

References

Further reading

External links

Related Articles

Wikiwand AI